An Open-Label Trial of Memantine for Cognitive Impairment in Patients with Posttraumatic Stress Disorder
Table 2
Change in RBANS scores during repeated measures.
Visit
Mean
SE
value
Total score
Baseline
77.8
2.0
<0.0001
Week 8
90.3
2.6
Week 16
92.2
2.7
Total score percentile
Baseline
10.6
1.6
<0.0001
Week 8
32.6
4.9
Week 16
35.8
5.4
Immediate memory
Baseline
82.8
2.5
<0.0001
Week 8
95.3
2.3
Week 16
94.6
2.7
Immediate memory percentile
Baseline
18.9
4.4
<0.0001
Week 8
39.8
5.3
Week 16
38.9
5.8
Visuospatial index score
Baseline
83.2
2.6
0.0001
Week 8
91.8
2.9
Week 16
97.6
3.1
Visuospatial percentile
Baseline
20.2
3.8
0.0002
Week 8
33.4
5.6
Week 16
45.8
5.9
Language
Baseline
85.7
2.2
0.0024
Week 8
93.9
1.9
Week 16
92.6
1.7
Language percentile
Baseline
22.0
3.7
0.0006
Week 8
36.7
3.5
Week 16
32.9
3.7
Attention
Baseline
79.9
2.7
0.0017
Week 8
92.0
3.0
Week 16
93.4
3.3
Attention percentile
Baseline
16.0
3.1
0.0009
Week 8
34.9
5.9
Week 16
38.4
6.3
Delayed memory
Baseline
83.1
3.5
0.0003
Week 8
91.1
3.6
Week 16
94.0
3.5
Delayed memory percentile
Baseline
24.0
4.4
0.0003
Week 8
37.9
5.6
Week 16
43.1
5.5
There was significant improvement in all RBANS scores, including language, attention, and immediate and delayed memory from baseline, week 8, and week 16.
